萬泰生物(603392.SH):總工程師李益民及副總經理李莎燕擬分別減持不超20萬股
格隆匯5月12日丨萬泰生物(603392.SH)公佈,公司總工程師李益民、副總經理李莎燕出於自身資金需求,擬採用集中競價交易方式減持公司IPO首次公開發行股份前取得的股票,上述公司董事、高級管理人員的減持計劃擬於公吿披露之日起15個交易日後的3個月內實施,減持數量分別為不超過20萬股、20萬股股份,分別不超過其各自持有公司股份數量的25%,合計通過集中競價交易方式減持不超過40萬股,佔公司當前總股本的0.0923%。
減持價格視市場情況確定。在集中競價減持計劃實施期間,如公司發生派發紅利、送紅股、轉增股本、增發新股或配股等股本除權、除息事項的,上述公司董事、高級管理人員可以根據公司股本變動對本次減持計劃進行相應調整,減持數量仍不會超過其各自持有公司股份數量的25%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.